Trestle Bio and Humacyte Form Research Collaboration

March 11, 2025—Trestle Biotherapeutics, Inc. recently announced a research collaboration with Humacyte, Inc. Trestle Bio is a preclinical-stage company developing implantable bioengineered kidney tissues for patients with end-stage renal disease (ESRD). Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale.

According to the company, the collaboration will explore technology synergies for bioengineering vascularized organs for transplantation. The aim of the research collaboration and material transfer agreement is for the two companies to explore potential avenues of technology integration. It will allow the companies to expand their research and development programs while exploring the interaction of Trestle Bio’s biofabricated human kidney tissues with Humacyte’s acelluar tissue engineered vessel-tyod (ATEV), to generate a human bioengineered kidney with vascular perfusion, stated the press release.

Trestle Bio advised that its stem cell-based, biofabricated human kidney tissues will be designed to provide sufficient levels of renal function to take ESRD patients off dialysis, delay their need for organ transplantation, and become the technological foundations from which transplantable bioengineered organs are biomanufactured. This is intended to address the global organ shortage, stated the company.

As noted in the press release, Humacyte recently announced FDA approval for its ATEV for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein grafting is not feasible. On February 26, 2025, Humacyte announced the commercial launch of the ATEV as Symvess.